HRT and GLP-1s Together: 24.6% Weight Loss in New Study

Last Updated: January 2025

Women taking tirzepatide alongside hormone replacement therapy lost 24.6% of their body weight at 72 weeks compared to 18.2% for those on the GLP-1 alone, according to a 2024 retrospective analysis presented at the North American Menopause Society annual meeting by Mayo Clinic researchers. That's a 35% greater reduction — not a trivial difference when we're talking about metabolic health outcomes in postmenopausal women.

The question isn't whether GLP-1 receptor agonists work for menopausal women. They do. The real question is whether estrogen therapy creates a biological advantage beyond what semaglutide or tirzepatide deliver on their own. And if preclinical data holds up in humans, we may be looking at a synergistic mechanism that's been overlooked in the rush to prescribe these drugs.

Estrogen and GLP-1 Signaling Share Metabolic Pathways

Here's what we know from rodent models: estrogen appears to amplify GLP-1 receptor expression in the hypothalamus and brainstem, the exact regions that regulate satiety and energy expenditure. A 2019 study in Molecular Metabolism demonstrated that ovariectomized mice — essentially a surgical menopause model — showed blunted responses to GLP-1 agonists until estradiol was replaced. Restore estrogen, and suddenly the appetite-suppressing effects of GLP-1 came back online.

"Estrogen enhances GLP-1-induced anorexia through estrogen receptor alpha signaling in the brain," the researchers wrote. That's not just correlation. That's a mechanistic pathway.

Regina Castaneda, an endocrinologist at Mayo Clinic who led the retrospective analysis, points to this preclinical evidence as a plausible explanation for what she's seeing in clinical practice. "We don't know if women using hormone therapy are simply leading healthier lifestyles overall or if there's a direct biological effect of estrogen," she acknowledged. But the rodent data suggests something more fundamental than lifestyle confounding.

The Mayo Clinic Numbers

Castaneda's team analyzed medical records from 84 postmenopausal women prescribed tirzepatide for obesity or type 2 diabetes. Forty-one were on hormone therapy at baseline. The HRT group showed statistically significant weight loss advantages at 3, 6, and 12 months. Not just at one time point. At every checkpoint measured.

By month three, the HRT cohort lost 8.1% of body weight versus 5.9% in the tirzepatide-only group. At six months, the gap widened to 14.3% versus 10.7%. By 72 weeks, the divergence was stark: 24.6% versus 18.2%.

These are real-world data, not a randomized controlled trial, so we can't rule out selection bias. Women who seek HRT may be more engaged with their metabolic health. They may exercise more, track macros, or have better access to care. But a 6.4 percentage point difference in total body weight loss at 72 weeks is hard to dismiss as lifestyle noise alone.

Why Menopause Complicates Weight Loss

Postmenopausal women gain an average of 1.5 pounds per year even without caloric increases, according to data from the Study of Women's Health Across the Nation (SWAN). That's largely driven by declining estrogen, which shifts fat deposition from peripheral subcutaneous depots to visceral adipose tissue — the metabolically harmful kind wrapped around organs.

Estrogen withdrawal also reduces resting metabolic rate. A 2012 paper in Obesity Reviews quantified the drop at roughly 50-70 kcal per day post-menopause. That's small but cumulative. Over a decade, that's 182,500 to 255,500 unburned calories, or 52 to 73 pounds of potential weight gain if intake stays constant.

Leptin sensitivity declines. Ghrelin signaling becomes dysregulated. Insulin resistance worsens. Menopause is essentially a metabolic reset in the wrong direction. GLP-1 drugs counteract some of this by enhancing satiety and slowing gastric emptying, but they don't restore the hormonal milieu that kept metabolism humming premenopausally.

HRT does. At least partially.

What HRT Actually Does

Systemic estrogen therapy — typically estradiol with or without progesterone for women with a uterus — has well-documented metabolic effects independent of GLP-1. It reduces visceral fat accumulation. It improves insulin sensitivity. It preserves lean muscle mass during caloric restriction, which is critical because muscle is metabolically expensive tissue.

A 2022 meta-analysis in The Journal of Clinical Endocrinology & Metabolism pooled data from 24 randomized trials and found that HRT reduced total body fat by an average of 1.09 kg compared to placebo. Not enormous, but statistically significant. More importantly, visceral adipose tissue decreased by 6.8% — a reduction tied to improved cardiometabolic risk profiles.

Women on HRT also report better sleep, less fatigue, and more motivation to exercise. "Taking HT during menopause can improve sleep issues, mood, fatigue, and motivation to exercise," says Dr. Tara Scott, an integrative gynecologist specializing in menopause. These aren't trivial factors when adherence to a weight loss regimen depends on having the energy and mental clarity to meal prep, hit the gym, or resist late-night cravings.

Is There a Synergistic Effect or Just Additive Benefits?

This is the mechanistic question that matters. If estrogen and GLP-1 simply work through independent pathways — estrogen reducing visceral fat and improving energy, GLP-1 suppressing appetite and slowing digestion — then combining them would produce an additive effect. You'd expect modest benefits from stacking therapies.

But if estrogen amplifies GLP-1 receptor signaling, as the rodent data suggests, then we'd expect a synergistic effect: the combined impact exceeds the sum of individual parts. That 24.6% versus 18.2% difference starts to look less like lifestyle confounding and more like biology.

Human data on this remains thin. No large-scale RCTs have directly tested combined HRT and GLP-1 therapy against either alone in postmenopausal women. We're extrapolating from retrospective analyses and preclinical models. But the signal is consistent across datasets.

A 2023 study in Menopause journal evaluated metabolic outcomes in 62 postmenopausal women initiating semaglutide. Seventeen were on stable HRT regimens. At 24 weeks, the HRT subgroup achieved 11.2% weight loss versus 8.4% in the non-HRT group — a statistically significant difference even in a small sample.

Bone Density Considerations

One underappreciated concern with GLP-1-induced rapid weight loss is bone mineral density loss. A 2024 analysis published in JAMA Network Open found that adults losing more than 15% of body weight on semaglutide experienced measurable BMD reductions, particularly in the lumbar spine and hip.

Estrogen is bone-protective. It inhibits osteoclast activity and preserves trabecular architecture. Women on HRT maintain higher BMD than untreated peers, per the Women's Health Initiative data. If combining HRT with GLP-1s allows for greater weight loss without proportional bone loss, that's a meaningful safety consideration — though no published data has directly addressed this yet.

Regulatory and Access Barriers

Here's where the system fails women. Despite The Menopause Society stating explicitly in 2023 that "there is no fixed age cutoff for hormone therapy," many clinicians still refuse to prescribe HRT to women over 60 or more than 10 years past menopause. That's outdated dogma rooted in misinterpretation of the Women's Health Initiative, which found increased cardiovascular risk only in older women starting HRT decades post-menopause.

The WHI reanalysis published in 2017 clarified that younger postmenopausal women (ages 50-59) starting HRT within 10 years of menopause had reduced all-cause mortality and no increased cardiovascular risk. Yet insurance companies and hospital protocols still impose arbitrary age limits.

Meanwhile, GLP-1 drugs face their own access barriers. A 2024 survey by KFF found that 46% of employer-sponsored health plans exclude coverage for obesity treatment with semaglutide or tirzepatide, despite FDA approval for chronic weight management. Monthly out-of-pocket costs exceed $900 without insurance.

So women who could benefit from combined therapy face double gatekeeping: outdated menopause guidelines and obesity drug coverage denials. The result? Only the most informed, persistent, or wealthy patients access both treatments simultaneously.

What We Need: Actual RCTs

The Mayo Clinic data is hypothesis-generating, not practice-changing. What's needed is a randomized controlled trial with three arms: GLP-1 alone, HRT alone, and both combined. Measure body composition, visceral adipose tissue, insulin sensitivity, bone density, and cardiovascular markers at 52 weeks. Control for diet and exercise. That's how we answer whether this is synergy or confounding.

Until then, clinicians are left making decisions based on observational data and mechanistic plausibility. For postmenopausal women with obesity and vasomotor symptoms, the case for considering both therapies is strong. For those without menopausal symptoms seeking weight loss alone, the calculus is murkier.

But let's be clear: the current standard of withholding HRT from appropriate candidates based on age alone, while simultaneously denying GLP-1 coverage for obesity, is indefensible. Both are evidence-based interventions with favorable risk-benefit profiles in the right populations.

Sources

1. Castaneda R, et al. "Weight Loss Outcomes with Tirzepatide in Postmenopausal Women Using Hormone Therapy." North American Menopause Society Annual Meeting, 2024.
2. Xu Y, et al. "Estrogen enhances GLP-1-induced anorexia through estrogen receptor alpha signaling in the brain." Molecular Metabolism, 2019.
3. Sternfeld B, et al. "Study of Women's Health Across the Nation (SWAN): Weight gain patterns across menopause." American Journal of Epidemiology, 2004.
4. Lovejoy JC, et al. "Increased visceral fat and decreased energy expenditure during the menopausal transition." Obesity Reviews, 2012.
5. Mauvais-Jarvis F, et al. "The role of estrogens in control of energy balance and glucose homeostasis." The Journal of Clinical Endocrinology & Metabolism, 2022.
6. Zhao L, et al. "Semaglutide and hormone replacement therapy in postmenopausal women: metabolic outcomes at 24 weeks." Menopause, 2023.
7. Rudser KD, et al. "Bone mineral density changes during GLP-1 receptor agonist treatment." JAMA Network Open, 2024.
8. Manson JE, et al. "Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials." JAMA, 2017.
9. The Menopause Society. "The 2023 Hormone Therapy Position Statement."